Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
US9655954B2 · kind B2 · utility
4Cited by
20References
20Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 8, 2015 |
| Grant date | May 23, 2017 |
| Priority date | — |
| Expiry date | Jul 8, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y301/04012
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to dose escalation enzyme replacement therapy using acid sphingomyelinase (ASM) for the treatment of human subjects having acid sphingomyelinase deficiency (ASMD), and, in particular, patients with non-neurological manifestations of Niemann-Pick Disease (NPD), and in certain embodiments, NPD type B.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.